Your browser doesn't support javascript.
loading
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
Perry, Jennifer A; Kiezun, Adam; Tonzi, Peter; Van Allen, Eliezer M; Carter, Scott L; Baca, Sylvan C; Cowley, Glenn S; Bhatt, Ami S; Rheinbay, Esther; Pedamallu, Chandra Sekhar; Helman, Elena; Taylor-Weiner, Amaro; McKenna, Aaron; DeLuca, David S; Lawrence, Michael S; Ambrogio, Lauren; Sougnez, Carrie; Sivachenko, Andrey; Walensky, Loren D; Wagle, Nikhil; Mora, Jaume; de Torres, Carmen; Lavarino, Cinzia; Dos Santos Aguiar, Simone; Yunes, Jose Andres; Brandalise, Silvia Regina; Mercado-Celis, Gabriela Elisa; Melendez-Zajgla, Jorge; Cárdenas-Cardós, Rocío; Velasco-Hidalgo, Liliana; Roberts, Charles W M; Garraway, Levi A; Rodriguez-Galindo, Carlos; Gabriel, Stacey B; Lander, Eric S; Golub, Todd R; Orkin, Stuart H; Getz, Gad; Janeway, Katherine A.
Afiliação
  • Perry JA; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215;
  • Kiezun A; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Tonzi P; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215;
  • Van Allen EM; The Broad Institute of MIT and Harvard, Cambridge, MA 02142; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215;
  • Carter SL; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Baca SC; The Broad Institute of MIT and Harvard, Cambridge, MA 02142; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215;
  • Cowley GS; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Bhatt AS; The Broad Institute of MIT and Harvard, Cambridge, MA 02142; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215;
  • Rheinbay E; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Pedamallu CS; The Broad Institute of MIT and Harvard, Cambridge, MA 02142; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215;
  • Helman E; The Broad Institute of MIT and Harvard, Cambridge, MA 02142; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215;
  • Taylor-Weiner A; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • McKenna A; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • DeLuca DS; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Lawrence MS; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Ambrogio L; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Sougnez C; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Sivachenko A; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Walensky LD; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215; Department of Pediatrics.
  • Wagle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215; Department of Medicine.
  • Mora J; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain;
  • de Torres C; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain;
  • Lavarino C; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, 08950 Barcelona, Spain;
  • Dos Santos Aguiar S; Department of Pediatric Oncology, Centro Infantil Boldrini, Campinas, 13083-210, Brazil; Center for Pediatric Research.
  • Yunes JA; Department of Pediatric Oncology, Centro Infantil Boldrini, Campinas, 13083-210, Brazil; Medical Genetics Department, Faculty of Medical Sciences, State University of Campinas, Campinas 13083-887, Brazil;
  • Brandalise SR; Department of Pediatric Oncology, Centro Infantil Boldrini, Campinas, 13083-210, Brazil;
  • Mercado-Celis GE; Subdirection of Basic Research, National Institute of Genomic Medicine, 14610, Mexico City, Mexico;
  • Melendez-Zajgla J; Subdirection of Basic Research, National Institute of Genomic Medicine, 14610, Mexico City, Mexico;
  • Cárdenas-Cardós R; Department of Oncology, National Institute of Pediatrics, 04530, Mexico City, Mexico;
  • Velasco-Hidalgo L; Department of Oncology, National Institute of Pediatrics, 04530, Mexico City, Mexico;
  • Roberts CW; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215; Department of Pediatrics.
  • Garraway LA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215; Department of Medicine.
  • Rodriguez-Galindo C; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215; Department of Pediatrics.
  • Gabriel SB; The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
  • Lander ES; The Broad Institute of MIT and Harvard, Cambridge, MA 02142; Department of Systems Biology, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; and.
  • Golub TR; The Broad Institute of MIT and Harvard, Cambridge, MA 02142; Department of Pediatrics, Howard Hughes Medical Institute, Chevy Chase, MD 20815.
  • Orkin SH; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215; Department of Pediatrics, Howard Hughes Medical Institute, Chevy Chase, MD 20815 stuart_orkin@dfci.harvard.edu gadgetz@broadinstitute.org kjaneway@partners.org.
  • Getz G; The Broad Institute of MIT and Harvard, Cambridge, MA 02142; Department of Pathology, Harvard Medical School, Boston, MA 02115; stuart_orkin@dfci.harvard.edu gadgetz@broadinstitute.org kjaneway@partners.org.
  • Janeway KA; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA 02215; Department of Pediatrics, stuart_orkin@dfci.harvard.edu gadgetz@broadinstitute.org kjaneway@partners.org.
Proc Natl Acad Sci U S A ; 111(51): E5564-73, 2014 Dec 23.
Article em En | MEDLINE | ID: mdl-25512523
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Osteossarcoma / Genoma Humano / Fosfatidilinositol 3-Quinases / Serina-Treonina Quinases TOR Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Osteossarcoma / Genoma Humano / Fosfatidilinositol 3-Quinases / Serina-Treonina Quinases TOR Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article